Colorectal Cancer Clinical Trials

Showing 21-40 of 2,972 trials

Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis

NCT07079462

Main objective: 1\. To compare the objective response rate (ORR) of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib and second-line standard treatment in the treatment of peritoneal metastasis of colorectal cancer. Secondary objectives: 1. To compare the disease control rate (DCR), duration of continuous remission (DoR), progression-free survival (PFS) and overall survival (OS) of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib and second-line standard treatment in the treatment of peritoneal metastasis of colorectal cancer. 2. To evaluate the safety and tolerability of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib.

Colorectal CancerPeritoneal (Metastatic) CancerFAPI PET

Fudan University40 participantsStarted Mar 2024

Shanghai, Shanghai Municipality, China • Shanghai, China

Not Yet RecruitingNA

Health Behavior Intervention for Colorectal Cancer Patients

NCT07632313

Develop a health behavior intervention plan based on patients' needs and preferences, and preliminarily apply and evaluate the feasibility and effectiveness of this intervention plan for patients with colorectal cancer.

Colorectal Cancer

Nanjing Medical University40 participantsStarted Jun 2026

Nanjing, Jiangsu, China

Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis

Health Behavior Intervention for Colorectal Cancer Patients

Related Searches

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

PrehabPal: A Digital Tool to Help Older Adults Prepare for Cancer Surgery

MAP- Versus Cardiac Index-Guided Hemodynamic Management in Colorectal Surgery

Optimising Colorectal Cancer Patient Pathways

Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer

Spectral Precise Image-Colon Cancer

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Acupuncture Pilot Study for Cancer-related Cognitive Function

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis

Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer

Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)

Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

How Emotional Granularity Helps Build Resilience in Young and Middle-Aged Colorectal Cancer Survivors